3Waheed S, Shaughnessy J D, Van Rhee F, et al. Inter- national staging system and metaphase cytogenetic abnor- malities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 proto- cols[J] Cancer, 2011,117(5) :1001-1009.
4Stabler A, Baur A, Bartl R, et al. Contrast enhancement and quantitative signal in MR imaging of mutiple myelo- ma: Assessment of focal and diffuse growth pattern in marrow correlated with biopsies and survival rates [ J ]. AJR Am J Roentgenol, 1996,167(4):1029.
5Baur Melnyk A, Buhmann S, Becker C, et al. Whole- body MRI versus whole-body MDCT for staging of multi- pie myeloma [ J ]. American Journal of Roentgenology, 2008,190 ( 4 ) : 1097-1104.
6Shortt C P, Gleeson T G, Breen K A, et al. Whole-Body MRI Versus PET in Assessment of Multiple Myeloma Dis- ease Activity [ J ]. American Journal of Roentgenology, 2009,192 ( 4 ) : 980-986.
7Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [J]. CA CaneerJClin, 2012, 62: 10-29.
8Brenner H, Gondos A, Puke D. Recent major improvement in long -term survival of" younger patients with multiple myeoma[J].Blood, 2008, 111 (5): 2521-2526.
9Ktihnemund A, Liebisch P, Bauchmtiller K, et al. ' Light - chain escape - multiple myeloma' - an escape phenomenon from plateau phase: report of the largest patient series using LC - monitoring [ J ]. J Cancer Res Clin Oncol, 2009, 135 (3) : 477 -484.
10Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains [J]. Haematologica, 2007, 92 (1) : 143 -144.
